[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@chavarriagaj](/creator/twitter/chavarriagaj) "#ESMO25 Dr. Srikala Sridhar @UHN presents phase X ALPACA trial of avelumab in advanced penile cancer: 🌍 Rare & aggressive tumor (38K/yr); no standard 2L tx options 💉 ORR XX% mDoR XX mo durable responses in a subset of pts ⛔ Fairly unwell pts: XXX% visceral mets XX% ECOG X X% platinum-unfit ✅ Well-tolerated promising signal for ICI in HPV+ GU tumors 🔬 Biomarker work & early setting trials needed @UroToday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979176683639808363) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-17T13:24Z XXX followers, XXX engagements "#ESMO25 @petegodolphin presents updated STOPCAP meta-analysis on prostate RT in de novo mHSPC 📊 X RCTs pooled (HORRAD STAMPEDE PEACE-1): 🧍♂ 59y FU 3.25.3y median OS 📌 RT + SoC vs SoC alone 🔹 OS: HR XXXX (95% CI 0.841.00; p=0.058) 🔹 PFS: HR XXXX (95% CI 0.810.95; p=0.002) ✅ 🔹 Subgroups: X bone mets: PFS HR 0.79; OS HR XXXX X mets: No OS/PFS benefit Low-volume: OS HR XXXX (8% 5y OS) High-volume: No benefit Docetaxel use No interaction (p=0.87) @Urotoday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979162741308035582) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-17T12:29Z XXX followers, 2739 engagements "📢 #ESMO25 @DRathkopf presents PROs from AMPLITUDE: Niraparib + AA + P in HRRm mHSPC 🧬 rPFS (HR 0.63) symptomatic progression (HR 0.50) 📊 FACT-G FACT-P EQ-5D-5L VAS scores stable across arms 🩺 Most bothersome AEs (HTN anemia) peaked early; HRQoL recovered ✅ 7685% on NIRA vs 8693% on PBO reported not at all/a little bit bothered by side effects ✅ High compliance w/ ePROs supports feasibility @UroToday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979163568575594699) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-17T12:32Z XXX followers, XXX engagements "#ESMO25 Dr. Rana McKay explores LAG-3 as biomarker in frontline RCC ICI 🧬 n=566 from Tempus DB stratified by LAG-3 RNA (Q1Q4) 🔹 LAG-3 immune cell infiltration 🔹 Liver mets in Q4 but no clear trend in ORR or OS across quartiles 🧪 LAG-3 alone may not predict ICI benefit 📢 Still adds to growing evidence of LAG-3s immunologic relevance @myESMO @UroToday" [X Link](https://x.com/chavarriagaj/status/1979800632815968618) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-19T06:43Z XXX followers, XXX engagements "#ESMO25 Dr. Ken Herrmann on scaling radioligand therapy: 📈 Global nuclear medicine market projected to hit $42B by 2033 Major gaps in imaging & treatment access across EU: ✔ Only 1233% of eligible mCRPC patients get PSMA PET Wait times for RLT initiation still XX weeks Potential solutions 🏥 Essens FastTrackPSMARLT cuts referraltherapy time to 4w 🧠 Initiatives like PSMA Academy & theranostics centers (UCLA ICPO) @UroToday @myESMO" [X Link](https://x.com/chavarriagaj/status/1979882447098786112) [@chavarriagaj](/creator/x/chavarriagaj) 2025-10-19T12:08Z XXX followers, 2082 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@chavarriagaj
"#ESMO25 Dr. Srikala Sridhar @UHN presents phase X ALPACA trial of avelumab in advanced penile cancer: 🌍 Rare & aggressive tumor (38K/yr); no standard 2L tx options 💉 ORR XX% mDoR XX mo durable responses in a subset of pts ⛔ Fairly unwell pts: XXX% visceral mets XX% ECOG X X% platinum-unfit ✅ Well-tolerated promising signal for ICI in HPV+ GU tumors 🔬 Biomarker work & early setting trials needed @UroToday @myESMO"
X Link @chavarriagaj 2025-10-17T13:24Z XXX followers, XXX engagements
"#ESMO25 @petegodolphin presents updated STOPCAP meta-analysis on prostate RT in de novo mHSPC 📊 X RCTs pooled (HORRAD STAMPEDE PEACE-1): 🧍♂ 59y FU 3.25.3y median OS 📌 RT + SoC vs SoC alone 🔹 OS: HR XXXX (95% CI 0.841.00; p=0.058) 🔹 PFS: HR XXXX (95% CI 0.810.95; p=0.002) ✅ 🔹 Subgroups: X bone mets: PFS HR 0.79; OS HR XXXX X mets: No OS/PFS benefit Low-volume: OS HR XXXX (8% 5y OS) High-volume: No benefit Docetaxel use No interaction (p=0.87) @Urotoday @myESMO"
X Link @chavarriagaj 2025-10-17T12:29Z XXX followers, 2739 engagements
"📢 #ESMO25 @DRathkopf presents PROs from AMPLITUDE: Niraparib + AA + P in HRRm mHSPC 🧬 rPFS (HR 0.63) symptomatic progression (HR 0.50) 📊 FACT-G FACT-P EQ-5D-5L VAS scores stable across arms 🩺 Most bothersome AEs (HTN anemia) peaked early; HRQoL recovered ✅ 7685% on NIRA vs 8693% on PBO reported not at all/a little bit bothered by side effects ✅ High compliance w/ ePROs supports feasibility @UroToday @myESMO"
X Link @chavarriagaj 2025-10-17T12:32Z XXX followers, XXX engagements
"#ESMO25 Dr. Rana McKay explores LAG-3 as biomarker in frontline RCC ICI 🧬 n=566 from Tempus DB stratified by LAG-3 RNA (Q1Q4) 🔹 LAG-3 immune cell infiltration 🔹 Liver mets in Q4 but no clear trend in ORR or OS across quartiles 🧪 LAG-3 alone may not predict ICI benefit 📢 Still adds to growing evidence of LAG-3s immunologic relevance @myESMO @UroToday"
X Link @chavarriagaj 2025-10-19T06:43Z XXX followers, XXX engagements
"#ESMO25 Dr. Ken Herrmann on scaling radioligand therapy: 📈 Global nuclear medicine market projected to hit $42B by 2033 Major gaps in imaging & treatment access across EU: ✔ Only 1233% of eligible mCRPC patients get PSMA PET Wait times for RLT initiation still XX weeks Potential solutions 🏥 Essens FastTrackPSMARLT cuts referraltherapy time to 4w 🧠 Initiatives like PSMA Academy & theranostics centers (UCLA ICPO) @UroToday @myESMO"
X Link @chavarriagaj 2025-10-19T12:08Z XXX followers, 2082 engagements
/creator/twitter::159184453/posts